Society of Urologic Oncology (SUO) 23rd Annual Meeting
SUO 2022 Prostate Cancer
- SUO 2022: Using Biomarkers and Somatic Testing to Guide Treatment Choice
- SUO 2022: External Validation of a Digital Pathology-Based AI Model Predicting Metastasis and Death in High and Very High Risk Men on NRG/RTOG 9902 Phase III Trial
- SUO 2022: Geographic Variation in Utilization of Doublet Therapy for Metastatic Prostate Cancer
- SUO 2022: The Joseph A. Smith Jr. Mentorship Award Lecture
- SUO 2022: Use of Exogenous Testosterone in The Setting Of Screening, Active Surveillance, and After Treatment of Localized Disease
SUO 2022 Bladder Cancer
- SUO 2022: “Remote” Monitoring in Urologic Cancer: The Case for Home Based Testing in Bladder Cancer
- SUO 2022: Utility of Cxbladder Monitor in Surveillance
- SUO 2022: BCG Naïve - FDA: 1 Year from Symposia
- SUO 2022: Looking Towards the Future: Non-Muscle Invasive Bladder Cancer Trials Reading Out in 24 Months
- SUO 2022: Intermediate Risk Non-Muscle Invasive Bladder Cancer: “New” Definitions
SUO 2022 Upper Tract Urothelial Carcinoma
- SUO 2022: Long-term Outcomes of Treatment with UGN-101, A Mitomycin-containing Reverse Thermal Gel, For Primary Chemoablation of Low-grade Upper Tract Urothelial Carcinoma (LG UTUC)
- SUO 2022: Comparison of Administration Route for UGN-101 on Upper Tract Urothelial Carcinoma: A Multi Center Evaluation
- SUO 2022: Early Experience with UGN-101 for the Treatment of Upper Tract Urothelial Cancer – A Multi-Center Evaluation of Practice Patterns and Outcomes